Loss-of-function experiments using siRNA or shRNA targeting ILK have demonstrated that knockdown of ILK represses EMT, tumor growth, and metastasis in tongue and prostate cancers through inactivation of the PI3K/AKT pathway134. The gene discussed is ILK; the disease is prostate cancer.